Published in Ann Intern Med on June 01, 2004
To butterfly or to needle: the specimen testing question. Ann Intern Med (2004) 0.75
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med (2007) 12.17
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst (2010) 4.20
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis (2009) 3.55
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) (2009) 2.42
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine (2008) 2.09
Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance. Cancer Epidemiol Biomarkers Prev (2011) 1.74
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin (2009) 1.66
Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res (2008) 1.60
Antibiotic prophylaxis before surgery vs after cord clamping in elective cesarean delivery: a double-blind, prospective, randomized, placebo-controlled trial. Arch Surg (2011) 1.59
Monocyte chemoattractant protein-1 serum levels in patients with breast cancer. Tumour Biol (2004) 1.46
Polymorphisms of the endothelial nitric oxide synthase gene in breast cancer. Breast Cancer Res Treat (2006) 1.46
Interleukin-10 -1082 G/A promoter polymorphism and pregnancy complications: results of a prospective cohort study in 1,616 pregnant women. Acta Obstet Gynecol Scand (2008) 1.45
Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecol Oncol (2006) 1.42
Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women. Cancer Epidemiol Biomarkers Prev (2010) 1.34
Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer. Clin Cancer Res (2007) 1.26
Expression of KLF5 is a prognostic factor for disease-free survival and overall survival in patients with breast cancer. Clin Cancer Res (2006) 1.24
Interleukin-1 and interleukin-6 gene polymorphisms and the risk of breast cancer in caucasian women. Clin Cancer Res (2005) 1.23
The neuronal guidance cue Slit2 induces targeted migration and may play a role in brain metastasis of breast cancer cells. Breast Cancer Res Treat (2007) 1.23
Plasma fibrinogen levels and prognosis in patients with ovarian cancer: a multicenter study. Oncologist (2009) 1.19
Association of elevated C-reactive protein levels with an impaired prognosis in patients with surgically treated endometrial cancer. Obstet Gynecol (2007) 1.17
Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol (2013) 1.13
Novel diamide insecticides: sulfoximines, sulfonimidamides and other new sulfonimidoyl derivatives. Bioorg Med Chem Lett (2012) 1.13
Characterization of benign and malignant breast lesions with computed tomography laser mammography (CTLM): initial experience. Invest Radiol (2005) 1.10
Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas. Clin Cancer Res (2005) 1.07
C-reactive protein is a prognostic parameter in patients with cervical cancer. Gynecol Oncol (2007) 1.07
CXCR4 is expressed in ductal carcinoma in situ of the breast and in atypical ductal hyperplasia. Breast Cancer Res Treat (2004) 1.06
Increased expression of matrix metalloproteinase 2 in uterosacral ligaments is associated with pelvic organ prolapse. Int Urogynecol J Pelvic Floor Dysfunct (2005) 1.06
Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo. Clin Cancer Res (2005) 1.05
Treatment of cervical intraepithelial neoplasia with topical imiquimod: a randomized controlled trial. Obstet Gynecol (2012) 1.03
An interleukin-6 gene promoter polymorphism influences the biological phenotype of ovarian cancer. Cancer Res (2003) 1.02
Fibrinogen plasma levels are an independent prognostic parameter in patients with cervical cancer. Am J Obstet Gynecol (2009) 1.00
Estrogen-metabolizing gene polymorphisms in the assessment of breast carcinoma risk and fibroadenoma risk in Caucasian women. Cancer (2004) 0.99
Relevance of gamma-glutamyltransferase--a marker for apoptotic balance--in predicting tumor stage and prognosis in cervical cancer. Gynecol Oncol (2011) 0.99
Vascular endothelial growth factor splice variants and their prognostic value in breast and ovarian cancer. Clin Cancer Res (2002) 0.99
Weak expression of focal adhesion kinase (pp125FAK) in patients with cervical cancer is associated with poor disease outcome. Clin Cancer Res (2006) 0.98
Serologic markers of autoimmunity in women with polycystic ovary syndrome. Fertil Steril (2009) 0.96
PROGINS receptor gene polymorphism is associated with endometriosis. Fertil Steril (2002) 0.94
Treatment with vaginal progesterone in women with low-grade cervical dysplasia: a phase II trial. Anticancer Res (2010) 0.93
Assisted reproductive techniques in patients with Klinefelter syndrome: a critical review. Fertil Steril (2004) 0.93
The perioperative morbidity of laparoscopic pelvic lymph node staging in patients with advanced cervical cancer. Anticancer Res (2008) 0.93
HMGA2 is associated with invasiveness but not a suitable marker for the detection of circulating tumor cells in breast cancer. Oncol Rep (2005) 0.93
Phytoestrogens in clinical practice: a review of the literature. Fertil Steril (2007) 0.93
Expression of MUC1 splice variants in benign and malignant ovarian tumours. Int J Cancer (2002) 0.92
A 9-Valent HPV Vaccine in Women. N Engl J Med (2015) 0.92
Comparison of p53 mutational status with mRNA and protein expression in a panel of 24 human breast carcinoma cell lines. Breast Cancer Res Treat (2003) 0.92
Periurethral connective tissue status of postmenopausal women with genital prolapse with and without stress incontinence. Acta Obstet Gynecol Scand (2003) 0.92
The presence of postmenopausal bleeding as prognostic parameter in patients with endometrial cancer: a retrospective multi-center study. BMC Cancer (2009) 0.91
Estrogen and progesterone receptor expression in patients with uterine leiomyosarcoma and correlation with different clinicopathological parameters. Anticancer Res (2003) 0.91
A common interleukin-6 gene promoter polymorphism influences the clinical characteristics of women with polycystic ovary syndrome. Fertil Steril (2004) 0.91
The intraoperative complication rate of nonobstetric dilation and curettage. Obstet Gynecol (2009) 0.91
External validation of a nomogram predicting overall survival of patients diagnosed with endometrial cancer. Gynecol Oncol (2012) 0.90
Role of the vaginally administered aromatase inhibitor anastrozole in women with rectovaginal endometriosis: a pilot study. Fertil Steril (2005) 0.90
The inflammation-based Glasgow Prognostic Score predicts survival in patients with cervical cancer. Int J Gynecol Cancer (2010) 0.90
Combined thrombophilic polymorphisms in women with idiopathic recurrent miscarriage. Fertil Steril (2003) 0.90
Prognostic value of lymph node ratio and clinicopathologic parameters in patients diagnosed with stage IIIC endometrial cancer. Obstet Gynecol (2012) 0.90
The cyclooxygenase-2 inhibitor rofecoxib (Vioxx) in the treatment of cervical dysplasia grade II-III A phase II trial. Eur J Obstet Gynecol Reprod Biol (2005) 0.90
Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis. Gynecol Oncol (2005) 0.89
Genotype distribution of estrogen receptor-alpha, catechol-O-methyltransferase, and cytochrome P450 17 gene polymorphisms in Caucasian women with uterine leiomyomas. Fertil Steril (2006) 0.89
Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients--a study of the OVCAD consortium. BMC Cancer (2013) 0.89
A novel training model for the loop electrosurgical excision procedure: an innovative replica helped workshop participants improve their LEEP. Am J Obstet Gynecol (2012) 0.88
Serum levels of heat shock protein 70 in patients with preeclampsia: a pilot-study. Wien Klin Wochenschr (2002) 0.88
Lack of association of TNFalpha gene polymorphisms and recurrent pregnancy loss in Caucasian women. J Reprod Immunol (2004) 0.88
Polymorphisms of the endothelial nitric oxide synthase gene in ovarian cancer. Gynecol Oncol (2002) 0.88
Ultrasound morphology of invasive lobular breast cancer is different compared with other types of breast cancer. Ultrasound Med Biol (2005) 0.88
Human progesterone receptor gene polymorphism PROGINS and risk for breast cancer in Austrian women. Breast Cancer Res Treat (2002) 0.88
Polymorphisms associated with thrombophilia and vascular homeostasis and the timing of menarche and menopause in 728 white women. Menopause (2005) 0.87
Contraceptive counselling and factors affecting women's contraceptive choices: results of the CHOICE study in Austria. Reprod Biomed Online (2011) 0.87
Serum C-reactive protein in the differential diagnosis of ovarian masses. Eur J Obstet Gynecol Reprod Biol (2009) 0.87
Genetic alterations in endometrial hyperplasia and cancer. Cancer Lett (2002) 0.87
A polymorphism of the interleukin-1 receptor antagonist plays a prominent role within the interleukin-1 gene cluster in vulvar carcinogenesis. Gynecol Oncol (2004) 0.87
Genetic variations of interleukin-1 and -6 genes and risk of cervical intraepithelial neoplasia. Gynecol Oncol (2011) 0.87
A polymorphism in the matrix metalloproteinase-1 gene promoter is associated with the prognosis of patients with ovarian cancer. Gynecol Oncol (2005) 0.86
Does increased health care spending afford better health care outcomes? Evidence from Austrian health care expenditure since the implementation of DRGs. Swiss Med Wkly (2012) 0.86
Role of p53 in G2/M cell cycle arrest and apoptosis in response to gamma-irradiation in ovarian carcinoma cell lines. Int J Oncol (2003) 0.86